Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

Inclusion Criteria:

1. Presence of thoracic aortic pathology deemed to warrant surgical repair whichrequires proximal graft placement in Zone 0-2.

2. Age ≥18 years at time of informed consent signature

3. Subject is capable of complying with protocol requirements, including follow-up

4. Informed Consent Form (ICF) is signed by Subject or legal representative

5. Must have appropriate proximal aortic landing zone.

6. Must have appropriate target branch vessel landing zone

7. For patients with aneurysm/isolated lesion, must have appropriate distal aorticlanding zone.

Exclusion Criteria:

1. Concomitant disease of the ascending aorta or aneurysm of the abdominal aortarequiring repair

2. Previous endovascular repair of the ascending aorta

3. Previous endovascular repair of the DTA with a non-Gore device

4. Surgery within 30 days prior to enrollment, with the exception of surgery forAscending Aortic Dissection and/or placement of vascular conduit for access

5. Infected aorta

6. Life expectancy <2 years

7. Myocardial infarction within 6 weeks prior to treatment

8. Stroke within 6 weeks prior to treatment, stroke defined as rapidly developingclinical signs of focal (or global) disturbance of cerebral function, lasting morethan 24 hours or leading to death, with no apparent cause other than that ofvascular origin.

9. Patient has a systemic infection and may be at increased risk of endovascular graftinfection

10. Pregnant female at time of informed consent signature

11. Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome

12. Participation in another drug or medical device study within one year of studyenrollment

13. Known history of drug abuse within one year of treatment

14. Presence of protruding and/or irregular thrombus and/or atheroma in the aortic archor ascending aorta

15. Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheathinsertion and the inability to use a conduit for vascular access

16. Planned coverage of celiac artery

17. Patient has known sensitivities or allergies to the device materials

18. Patient has known hypersensitivity or contraindication to anticoagulants or contrastmedia, which is not amenable to pre-treatment

19. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or knownhypersensitivity to heparin

20. Patient with a history of a hypercoagulability disorder and/or hypercoagulabilitystate

21. Diameter taper outside of the device sizing range between proximal and distallanding zones of aorta and the inability to use additional devices of differentdiameters to compensate for the taper

22. Mycotic aneurysm

23. Persistent refractory shock (systolic blood pressure <90 mm Hg)

24. Patient has body habitus or other medical condition which prevents adequatevisualization of the aorta

25. Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) <30 or currently requiring dialysis